ReviewNature reviews. Urology2018
An interdisciplinary consensus on the management of bone metastases from renal cell carcinoma.
Review in Nature reviews. Urology, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 53 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
53 citing papers in PubMed.
- Nivolumab plus cabozantinib versus sunitinib in first-line treatment for advanced renal cell carcinoma (CheckMate 9ER): long-term follow-up results from an open-label, randomised, phase 3 trial.The Lancet. Oncology · 2022Trial
- Survival nomogram for patients with bone metastatic renal cell carcinoma: A population-based study.International braz j urol : official journal of the Brazilian Society of UrologyTrial
- The Construction and Validation of a new Predictive Model for Overall Survival of Clear Cell Renal Cell Carcinoma Patients with Bone Metastasis Based on Machine Learning Algorithm.Technology in cancer research & treatmentTrial
- Should Metastatic Site Inform First-Line Therapy in Clear Cell Renal Cell Carcinoma?Targeted oncology · 2026Review
- Metastatic renal cell carcinoma: risk of rapid progression to pathological fractures and factors influencing post-treatment survival - a Swedish Nationwide cohort study.Journal of bone oncology · 2026Article
- Clear Cell Renal Cell Carcinoma with Synchronous Bladder Metastasis: Diagnostic, Surgical, and Pathological Insights from a Rare Presentation.Journal of clinical medicine · 2026Article
- First-Line Treatment Strategies in IMDC Favourable-Risk Metastatic Clear Cell Renal Cell Carcinoma.Oncology research · 2026Review
- Clear cell renal cell carcinoma presenting as isolated symptomatic lumbar vertebral metastasis: a case report.Frontiers in oncology · 2026Article
- The molecular axis hnRNPU/circKCNK2/EDC4/IL-11 aggravates osteolytic bone metastasis of RCC.Oncogene · 2025Article
- Beyond the Scalpel: the Role of Image-Guided Thermal Ablation in Management of Metastatic Renal Cell Carcinoma in the Era of Immunotherapy.Cardiovascular and interventional radiology · 2025Review
- Proximal Femoral Replacement or Revision Stem Hemiarthroplasty for Metastatic Disease of the Proximal Femur-Is There Any Notable Difference?Journal of the American Academy of Orthopaedic Surgeons. Global research & reviews · 2025Observational
- Single-Cell Analysis Reveals that Vitamin C Inhibits Bone Metastasis of Renal Cancer via Cell Cycle Arrest and Microenvironment Remodeling.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2025Article
- Article
- Invasion and metastasis in cancer: molecular insights and therapeutic targets.Signal transduction and targeted therapy · 2025Review
- New players in the landscape of renal cell carcinoma bone metastasis and therapeutic opportunities.International journal of cancer · 2025Review
- Predictive Factors for Failed Nonsurgical Management of Long Bone Metastasis and Myeloma.Journal of the American Academy of Orthopaedic Surgeons. Global research & reviews · 2025Article
- Efficacy of innovative systemic treatments in combination with radiotherapy for bone metastases: a GEMO (the European Study Group of Bone Metastases) state of the art.Cancer metastasis reviews · 2025Review
- Article
- A novel nomogram for survival prediction in renal cell carcinoma patients with brain metastases: an analysis of the SEER database.Frontiers in immunology · 2025Article
- Sites of Metastasis and Survival in Metastatic Renal Cell Carcinoma: Results From the Korean Renal Cancer Study Group Database.Journal of Korean medical science · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
14 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Bone is a major site of haematogenous tumour cell spread in renal cell carcinoma (RCC), and most patients with RCC will develop painful and functionally disabling bone metastases at advanced disease stages. The prognosis of these patients is generally poor and the treatment is, therefore, aimed at palliation. However, RCC-associated bone metastases can be curable in select patients. Current data support a multimodal management strategy that includes wide resection of lesions, radiotherapy, systemic therapy, and other local treatment options, which can improve quality of life and survival. Nevertheless, the optimal approach for metastatic bone disease in RCC has not yet been defined and practical recommendations are rare. To improve the management and outcomes of patients with RCC and bone metastases, the International Kidney Cancer Coalition and the interdisciplinary working group on renal tumours of the German Cancer Society convened a meeting of experts with a global perspective to perform an unstructured review and elaborate on current treatment strategies on the basis of published data and expertise. The panel formulated recommendations for the diagnosis and treatment of patients with RCC and metastasis to the bone. Furthermore, the experts summarized current challenges and unmet patient needs that should be addressed in the future.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.